Table 2 Changes in MRI volumetric outcome measures from baseline in patients with Alzheimer disease (AD) in a 52-week, randomised, double-blind, placebo-controlled trial of the effects of memantine on brain morphology and metabolism

	Imaging endpoint	Assessment	n	Total group	n	Placebo	n	Memantine
Volumetry	Brain volume change (%)	Week 26	29	−0.6 (1.69)	15	−0.8 (2.04)	14	−0.6 (1.23)
	Brain volume change (%)	Week 52	21	−2.1 (2.01)	12	−2.0 (1.92)	9	−2.3 (2.22)
	Hippocampal volume change (%)	Week 26	29	−1.9 (2.82)	15	−2.4 (2.01)	14	−2.0 (2.70)
	Hippocampal volume change (%)	Week 52	21	−2.7 (3.64)	12	−4.0 (3.99)	9	−2.4 (2.81)

Numbers are mean (SD). Differences between treatment groups were non-significant based on analysis of covariance (ANCOVA).